Potential for serotonergic agents to treat elevated intraocular pressure and glaucoma: Focus on 5-HT2 receptor agonists

Expert Review of Ophthalmology

Volumn 6, Issue 1, 2011, Pages 105-120

  Sharif, Najam A ^a   May, Jesse A ^a  

^a ALCON RESEARCH LTD   (United States)

Author keywords

eye; glaucoma; intraocular pressure; serotonin

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 [5 (2 THIENYLMETHOXY) 3 INDOLYL] 2 PROPANAMINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; 8 [5 [2,4 DIMETHOXY 5 (4 TRIFLUOROMETHYLPHENYLSULFONAMIDO)PHENYL] 5 OXOPENTYL] 1,3,8 TRIAZASPIRO[4.5]DECANE 2,4 DIONE; AL 34662; AL 6598; ALPHA METHYLSEROTONIN; BETAXOLOL; BRIMONIDINE; BRINZOLAMIDE; CABERGOLINE; CINANSERIN; DORZOLAMIDE; FLESINOXAN; FLUOXETINE; KETANSERIN; PILOCARPINE; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; RITANSERIN; RS 127445; SDZSER 082; SEROTONIN 2 AGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR; TRAVOPROST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLINANSERIN;

CALCIUM MOBILIZATION; CONCENTRATION RESPONSE; COST OF ILLNESS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; NONHUMAN; OPEN ANGLE GLAUCOMA; PATHOGENESIS; PROTEIN LOCALIZATION; RETINA GANGLION CELL; REVIEW; SEROTONINERGIC SYSTEM; SPECIES DIFFERENCE; TRABECULAR MESHWORK;

EID: 79951873808     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/eop.10.69     Document Type: Review

References (134)

1. Conroy DM, Acton ML. New therapies to treat sight loss in an aging population. Drug Discov. Today 15, 256-259 (2010).
2. Wostyn P, Audenaert K, De Deyn PP. Alzheimer's disease and glaucoma: is there a causal relationship? Br. J. Ophthalmol. 93, 1557-1559 (2009).
3. Weinreb RN, Khaw PT. Primary open angle glaucoma. Lancet 363, 1711-1720 (2004).
4. Congdon N, O'Colmain B, Klaver CC et al. Causes and prevalence of visual impairment among (Pubitemid 38456282)
5. Resnikoff S, Pascolini D, Etya'ale D et al. Global data on visual impairment in the year 2002. Bull. World Health Organ. 82, 844-851 (2004). (Pubitemid 39573742)
6. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 90, 262-267 (2006). (Pubitemid 43325451)
7. Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv. Ophthalmol. 53, S3-S10 (2008).
8. Tamm ER, Fuchshofer R. What increases outflow resistance in primary open-angle glaucoma? Surv. Ophthalmol. 52(Suppl. 2), S101-S104 (2007). (Pubitemid 350060958)
9. Tamm ER. The trabecular meshwork outflow pathways: structural and functional aspects. Exp. Eye Res. 88, 648-655 (2009).
10. Alm A, Nilsson SF. Uveoscleral outflow -a review. Exp. Eye Res. 88, 760-768 (2009).
11. Acott TS, Kelley MJ. Extracellular matrix turnover and outflow resistance. Exp. Eye Res. 86, 543-561 (2008).
12. Keller KE, Aga M, Bradley JM, Kelley MJ, Acott TS. Extracellular matrix turnover and outflow resistance. Exp. Eye Res. 88, 676-682 (2009).
13. Tan, JCH, Peters DM, Kaufman PL. Recent developments in understanding the pathophysiology of elevated intraocular pressure. Curr. Opin. Ophthalmol. 17, 168-174 (2006). (Pubitemid 43790813)
14. Rhee DJ, Haddadin RI, Kang MH, Oh DJ. Matricellular proteins in the trabecular meshwork. Exp. Eye Res. 88, 694-703 (2009).
15. Okuno T, Oku H, Sugiyama T, Ikeda T. Glutamate level in optic nerve head is increased by artificial elevation of intraocular pressure in rabbits. Exp. Eye Res. 82, 465-470 (2006). (Pubitemid 43138960)
16. Yorio T, Krishnamoorthy R, Prasanna G. Endothelin: is it a contributor to glaucoma pathophysiology? J. Glaucoma 11, 259-270 (2002). (Pubitemid 34620104)
17. Sossi N, Anderson DR. Blockage of axonal transport in optic nerve induced by elevation of intraocular pressure. Effect of arterial hypertension induced by angiotensin I. Arch. Ophthalmol. 101, 94-97 (1983). (Pubitemid 13167179)
18. Kong GY, Van Bergen NJ, Trounce IA, Crowston JG. Mitochondrial dysfunction and glaucoma. J. Glaucoma 18, 93-100 (2009).
19. Shifera AS, Trivedi S, Chau P, Bonnemaison LH, Iguchi R, Alvarado J. Constitutive secretion of chemokines by cultured human trabecular meshwork cells. Exp. Eye Res. 91, 42-47 (2010).
20. Hazin R, Hendrick AM, Kahook MY. Primary open-angle glaucoma: diagnostic approaches and management. J. Natl Med. Assoc. 101, 46-50 (2009).
21. Clark AF, Yorio T. Ophthalmic drug discovery. Nat. Rev. Drug Discov. 2, 448-459 (2003). (Pubitemid 37361726)
22. Sharif NA, Klimko P. CNS: ophthalmic Agents. In:Comprehensive Medicinal Chemistry II (Volume 6, Chapter 12) . Taylor JB, Triggle DJ (Eds). Elsevier, Oxford, UK, 297-320 (2007).
23. McKinnon SJ, Goldberg LD, Peeples P, Walt JG, Bramley TJ. Current management of glaucoma and the need for complete therapy. Am. J. Manag. Care 14, S20-S27 (2008). (Pubitemid 351341925)
24. Webers CA, Beckers HJ, Nuijts RM, Schouten JS. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging 25, 729-759 (2008).
25. Costagliola C, dell'Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F. Pharmacotherapy of intraocular pressure: part I. parasympathomimetic, sympathomimetic and sympatholytics. Expert Opin. Pharmacother. 10, 2663-2677 (2009).
26. Costagliola C, dell'Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F. Pharmacotherapy of intraocular pressure: part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin. Pharmacother. 10, 2859-2870 (2009).
27. Whitson JT. Glaucoma: a review of adjunctive therapy and new management strategies. Expert Opin. Pharmacother. 8, 3237-3249 (2007).
28. Bournias TE, Lai J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. Ophthalmology 116, 1719-1724 (2009).
29. Galanopoulos A, Goldberg I. Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension. Clin. Ophthalmol. 3, 117-122 (2009).
30. Levins LA, Peeples P. History of neuroprotection and rationale as a therapy for glaucoma. Am. J. Manag. Care 14, S11-S14 (2008). (Pubitemid 351341923)
31. Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol. 87, 450-454 (2009).
32. Ehinger B, Floren I. Retinal indolamine accumulating neurons. Neurochem. Int. 1, 209-229 (1980).
33. Moro F, Scapagnin U, Scaletta S, Drago F. Serotonin nerve endings in the regulation of papillary diameter. Ann. Ophthalmol. 13, 487-490 (1981). (Pubitemid 11096999)
34. Tobin AB, Unger W, Osborne NN. Evidence for presence of serotonergic nerves and receptors in the iris-ciliary body complex of the rabbit. J. Neurosci. 8, 3713-3721 (1988).
35. Matsumoto Y, Ueda S, Kawata M. Morphological characterization and distribution of indolamine-accumulating cells in the rat retina. Acta Histochem. Cytochem. 25, 45-51 (1992).
36. Redburn DA, Churchill L. An indoleamine system in photoreceptor cell terminals of the Long-Evans rat retina. J. Neurosci. 7, 319-329 (1987). (Pubitemid 17017462)
37. Cooper RL, Constable IJ, Davidson L. Cathecholamines in aqueous humor of glaucoma patients. Aust. J. Ophthalmol. 12, 345-349 (1984). (Pubitemid 15085756)
38. Martin XD, Brennan MC, Lichter PR. Serotonin in human aqueous humor. Ophthalmology 95, 1221-1226 (1988).
39. Martin XD, Malina HZ, Brennan MC, Hendrickson PH, Lichter PR. The ciliary body -the third organ found to synthesize indoleamines in humans. Eur. J. Ophthalmol. 2, 67-72 (1992).
40. Trope GE, Sole M, Aedy L, Madapallimattam A. Levels of norepinephrine, epinephrine, dopamine, serotonin and N-acetylserotonin in aqueous humor. Can. J. Ophthalmol. 22, 152-154 (1987). (Pubitemid 17111513)
41. Veglio F, De Sanctis U, Schiavone D et al. Evaluation of serotonin levels in human aqueous humor. Ophthalmologica 212, 160-163 (1998). (Pubitemid 28141000)
42. Boerrigter RM, Sietsema JV, Kema IP. Serotonin (5-HT) and the rat's eye. Some pilot studies. Doc. Ophthalmol. 82, 141-150 (1992). (Pubitemid 23140326)
43. Pootanakit K, Brunken WJ. 5-HT1A and 5-HT7 receptor expression in the mammalian retina. Brain Res. 875, 152-156 (2002).
44. Pootanakit K, Prior KJ, Hunter DJ, Brunken WJ. 5-HT2A receptors in the rabbit retina: potential presynaptic modulators. Vis. Neurosci. 16, 221-230 (1999). (Pubitemid 29188116)
45. Nash M, Flanigan T, Leslie R, Osborne NN. Serotonin-2A receptor mRNA expression in rat retinal pigment epithelial cells. Ophthalmic Res. 31, 1-4 (1993).
46. Turner HC, Alvarez LJ, Candia OA, Bernstein AM. Characterization of serotonergic receptors in rabbit, porcine and human conjunctivae. Curr. Eye Res. 27, 205-215 (2003). (Pubitemid 37315479)
47. Chidlow G, Le Corre, Osborne NN. Localization of 5-hydroxytryptamine-1A and 5-hydroxytryptamine-7 receptors in rabbit ocular and brain tissues. Neuroscience 87, 675-689 (1998). (Pubitemid 28396553)
48. Chidlow G, Hiscott PS, Osborne NN. Expression of serotonin receptor mRNAs in human ciliary body: a polymerase chain reaction study. Graefe's Arch. Clin. Exp. Ophthalmol. 242, 259-264 (2004). (Pubitemid 38477213)
49. Sharif NA, Senchyna M. Serotonin receptor subtype mRNA expression in human ocular tissues determined by RT-PCR. Mol. Vis. 12, 1040-1047 (2006). (Pubitemid 44340518)
50. Mallorga P, Sugrue MF. Characterization of serotonin receptors in the iris-ciliary body of the albino rabbit. Curr. Eye Res. 6, 527-532 (1987). (Pubitemid 17039764)
51. Sharif NA, Kelly CR, Crider JY, Senchyna M. RT-PCR mapping of serotonin receptor subtype mRNAs in human ciliary body and trabecular meshwork. Assoc. Res. Vis. Ophthalmol. Abst. 3688 (2005).
52. Chidlow G, DeSantis LM, Sharif NA, Osborne NN. Characteristics of [3H]-5-hydroxytryptamine binding to iris-ciliary body tissue of the rabbit. Invest. Ophthalmol. Vis. Sci. 36, 2238-2245 (1995).
53. Sharif NA, Kelly CR, Crider JY, Davis TL. Serotonin-2 (5-HT2) receptor-mediated signal transduction in human ciliary muscle cells: role in ocular hypotension. J. Ocul. Pharmacol. Ther. 22, 389-401 (2006). (Pubitemid 46106477)
54. Neufeld AH, Ledgard SE, Jumblatt MM, Klyce SD. Serotonin-stimulated cyclic AMP synthesis in the rabbit corneal epithelium. Invest. Ophthalmol. Vis. Sci. 23, 193-198 (1982). (Pubitemid 12051497)
55. Blazynski C, Ferrendelli JA, Cohen AI. Indolamine-sensitive adenylate cyclase in rabbit retina: characterization and distribution. J. Neurochem. 45, 440-447 (1985). (Pubitemid 15233943)
56. Akhtar RA. Effects of norepinephrine and 5-hydroxytryptamine on phosphoinositide-PO4 turnover in rabbit cornea. Exp. Eye Res. 44, 849-862 (1987). (Pubitemid 17113224)
57. Cutcliffe N, Osborne NN. Serotonergic and cholinergic stimulation of inositol phosphate formation in the rabbit retina. Evidence for the presence of serotonin and muscarinic receptors. Brain Res. 421, 95-104 (1987). (Pubitemid 18021617)
58. Barnett NL, Osborne NN. The presence of serotonin (5-HT1) receptor negatively coupled to adenylate cyclase in rabbit and human iris-ciliary process. Exp. Eye Res. 57, 209-216 (1993). (Pubitemid 23252714)
59. Tobin AB, Osborne NN. Evidence for the presence of serotonin receptors negatively coupled to adenylate cyclase in the rabbit iris-ciliary body. J. Neurochem. 53, 686-691 (1989). (Pubitemid 19207358)
60. Osborne NN, Ghazi H. 5-HT1A receptors positively coupled to cAMP formation in the rabbit retina. Neurochem. Int. 19, 407-511 (1991).
61. Osborne NN, Fitzgibbon F, Nash M, Liu NP, Leslie R, Cholewinski A. Serotonergic, 5-HT2, receptor-mediated phosphoinositide turnover and mobilization of calcium in cultured rat retinal pigment epithelium cells. Vis. Res. 33, 2171-2179 (1993). (Pubitemid 23266215)
62. Crider JY, Williams GW, Drace CD, Katoli P, Senchyna M, Sharif NA. Pharmacological characterization of a serotonin receptor (5-HT7) stimulating cAMP production in human corneal epithelial cells. Invest. Ophthalmol. Vis. Sci. 44, 4837-4844 (2003). (Pubitemid 37315298)
63. Inoue-Matsuhisa E, Moroi SE, Takenaka H, Sogo S, Mano T. 5-HT2 receptor-mediated phosphoinositide hydrolysis in bovine ciliary epithelium. J. Ocular Pharmacol. Ther. 19, 55-62 (2003). (Pubitemid 36249880)
64. Sharif NA, Kelly C, McLaughlin MA. Human trabecular meshwork cells express functional serotonin-2A (5-HT2A) receptors: role in IOP reduction. Invest. Ophthalmol. Vis. Sci. 47, 4001-4010 (2006). (Pubitemid 46044317)
65. Harris LC, Awe SO, Opere CA, Leday AM, Ohia SE, Sharif NA. [3H]Serotonin release from bovine iris-ciliary body: pharmacology of pre-junctional serotonin (5-HT7) autoreceptors. Exp. Eye Res. 73, 59-67 (2001). (Pubitemid 32977965)
66. Harris LC, Awe SO, Opere CA, LeDay AM, Ohia SE, Sharif NA. Pharmacology of serotonin receptors modulating electrically-induced [3H]norepinephrine release from isolated mammalian iris-ciliary bodies. J. Ocul. Pharmacol. Ther. 18, 339-348 (2002). (Pubitemid 34977656)
67. Lograno MS, Romano MR. Pharmacological characterization of the 5-HT1A, 5-HT2 and 5-HT3 receptors in the bovine ciliary muscle. Eur. J. Pharmacol. 464, 69-74 (2003). (Pubitemid 36205067)
68. Mangel SS, Brunken WJ. The effects of serotonin drugs on horizontal and ganglion cells in the rabbit retina. Vis. Neurosci. 8, 213-218 (1992).
69. Brunken WJ, Jin XT, Pis-Lopez AM. The properties of the serotonergic system in the retina. Prog. Ret. Res. 16, 75-99 (1993).
70. Brunken WJ, Jin XT. A role for 5-HT3 receptors in visual processing in the mammalian retina. Vis. Neurosci. 10, 511-522 (1993).
71. Brunken WJ, Daw NW. The effects of serotonin agonists and antagonists on the response properties of complex ganglion cells of the rabbit retina. Vis. Neurosci. 1, 181-188 (1988).
72. Klyce SD, Palkama KA, Harkone M et al. Neural serotonin stimulates chloride transport in the rabbit corneal epithelium. Invest. Ophthalmol. Vis. Sci. 23, 181-192 (1982). (Pubitemid 12051496)
73. Chiang TS. Effects of intravenous infusions of histamine, 5-hydroxytryptamine, bradykinin and prostaglandins on intraocular pressure. Arch. Int. Pharmacodyn. Ther. 207, 131-138 (1974).
74. Costagliola C, Parmeggiani F, Sebastiani A. SSRIs and intraocular pressure modifications: evidence, therapeutic implications and possible mechanisms. CNS Drugs 18, 475-484 (2004). (Pubitemid 38829944)
75. Krootila K, Palkama A, Uusitalo H. Effects of serotonin and its antagonist (ketanserin) on intraocular pressure in the rabbit. J. Ocul. Pharmacol. 3, 279-290 (1987). (Pubitemid 18063029)
76. Meyer-Bothling U, Bron AJ, Osborne NN. Topical application of serotonin or the 5-HT1-agonist 5-CT on intraocular pressure in rabbits. Invest. Ophthalmol. Vis. Sci. 34, 3035-3042 (1993). (Pubitemid 23269160)
77. Chu TC, Ogidigben MJ, Potter DE. 8-OH-DPAT-induced ocular hypotension: sites and mechanisms of action. Exp. Eye Res. 69, 227-238 (1999). (Pubitemid 29369296)
78. Chidlow G, Nash MS, DeSantis L, Osborne NN. The 5-HT1A receptor agonist 8-OH-DPAT lowers intraocular pressure in normotensive NZW rabbits. Exp. Eye Res. 69, 587-593 (1999). (Pubitemid 30046883)
79. Chidlow G, Cupido A, Melena J, Osborne NN. Flesinoxan, a 5-HT1A receptor agonist/5-HT1-adrenoceptor antagonist, lowers intraocular pressure in NZW rabbits. Curr. Eye Res. 23, 144-153 (2001). (Pubitemid 34499638)
80. May JA, McLaughlin MA, Sharif NA, Hellberg MR, Dean TR. Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. J. Pharmacol. Exp. Ther. 306, 301-309 (2003). (Pubitemid 36734385)
81. Chang FW, Burke JA, Potter DE. Mechanism of ocular hypotensive action of ketanserin. J. Ocular Pharmacol. 1, 137-147 (1985). (Pubitemid 17029803)
82. Chiou GC, Li BH. Ocular hypotensive actions of serotonin antagonist-ketanserin and analogs. J. Ocular Pharmacol. Ther. 8, 11-21 (1992).
83. Costagliola C, Iuliano G, Rinaldi M, Russo V, Scibelli G, Mastropasqua L. Effect of topical ketanserin administration on intraocular pressure. Br. J. Pharmacol. 77, 344-348 (1993). (Pubitemid 23193379)
84. Mastropasqua L, Costagliola C, Ciancaglini M, Carpineto P, Gallenga PE. Ocular hypotensive effect of ketanserin in patients with primary open angle glaucoma. Acta. Ophthalmol. Scand. Suppl. 224, 24-25 (1997). (Pubitemid 28184911)
85. Takat D, Guler C, Arici M, Topalkara A, Erdogan H. Effect of ketanserin administration on intraocular pressure. Ophthalmologica 215, 419-423 (2001). (Pubitemid 34008788)
86. Takenaka H, Mano T, Maeno T, Okada M, Okano Y, Mitsuka M. The effect of anplag (sarpogrelate HCl), novel selective 5-HT2 antagonist on intraocular pressure in glaucoma patients. Invest. Ophthalmol. Vis. Sci. 36, S734 (1995).
87. Cernerud M, Lundstrom H, Nilsson BM, Thor M. Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones. US Patent 7244722 (2007).
88. Berthold M, Crossley, R, Ward T. Imidazo[1,5-a]pyridine or imidazo[1,5-a] piperidine derivatives and their use for the preparation of medicaments against 5-HT2A receptor-related disorders. World Patent 2005/021545 A1 (2005).
89. Hoyer D, Clarke DE, Fozard JR et al. VII. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharm. Rev. 46, 157-203 (1994). (Pubitemid 24185150)
90. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71, 533-554 (2002). (Pubitemid 34219205)
91. Oshika T, Araie A, Sugiyama T, Nakajima M, Azuma I. Effect of bunazosin hydrochloride on intraocular pressure and aqueous humor dynamics in normotensive human eyes. Arch. Ophthalmol. 109, 1569-1574 (1991).
92. Wang RF, Lee PY, Mittag TW, Podos SM, Serle JB. Effect of 5-methyl-urapidil, an a-1a-adrenergic antagonist and 5-hydroxytrptamine-1A agonist, on aqueous humor dynamics in monkeys and rabbits. Curr. Eye Res. 16, 769-775 (1997). (Pubitemid 27354975)
93. Yoshio R, Taniguchi T, Itoh H, Muramatsu I. Affinity of serotonin receptor antagonists and agonists to recombinant and native a1-adrenoceptor subtypes. Jpn J. Pharmacol. 86, 189-195 (2001).
94. Sharif NA, McLaughlin MA, Kelly CR. AL-34662: a potent, selective and efficacious ocular hypotensive serotonin-2 receptor agonist. J. Ocular Pharmacol. Ther. 23, 1-13 (2007). (Pubitemid 46449294)
95. May JA, Dantanarayana AP, Zinke PW, McLaughlin MA, Sharif NA. 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J. Med. Chem. 49, 318-328 (2006). (Pubitemid 43077344)
96. May JM, Chen H-H, Rusinko A, Lynch VM, Sharif NA, McLaughlin MA. A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano-[3,2-e] indole. J. Med. Chem. 46, 4188-4195 (2003). (Pubitemid 37122461)
97. Sharif NA, McLaughlin, MA, Kelly CR et al. Cabergoline: pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in cynomolgus monkey eyes. Exp. Eye Res. 88, 386-397 (2006).
98. May JA, Dean TR, Sharif NA, Hellberg MR. Serotonergic 5-HT2 agonists for treating glaucoma. US Patent 6664286 B1 (2003).
99. Gabelt BT, Okka M, Dean TR, Kaufman PL. Aqueous humor dynamics in monkeys after topical R-DOI. Invest. Ophthalmol. Vis. Sci. 46, 4691-4696 (2005). (Pubitemid 44264571)
100. Kehne JH, Baron BM, Carr AA et al. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther. 277, 968-981 (1996).
101. .101 Wainscott DB, Lucaites VL, Kursar JD, Baez M, Nelson DL. Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences. J. Pharmacol. Exp. Ther. 276, 720-726 (1996).
102. Kennett GA, Wood MD, Bright F et al. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36, 609-620 (1997). (Pubitemid 27272106)
103. Wood MD, Thomas DR, Gager TL et al. Pharmacological characterisation of the human 5-HT2B and 5-HT2C receptors in functional studies. Pharmacol. Rev. Commun. 9, 259-268 (1997). (Pubitemid 28056781)
104. Porter RHP, Benwell KR, Lamb H et al. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Brit. J. Pharmacol. 128, 13-20 (1999). (Pubitemid 29425262)
105. Jerman JC, Brough SJ, Gager T et al. Pharmacological characterization of human 5-HT2 receptor subtypes. Eur. J. Pharmacol. 414, 23-30 (2001). (Pubitemid 32174871)
106. Weinreb RN, Kashiwagi K, Kashiwagi F et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest. Ophthalmol. Vis. Sci. 38, 2772-2780 (1997). (Pubitemid 28009399)
107. Wiederholt M, Thieme H, Stumpff F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog. Retinal Eye Res. 19, 271-295 (2000). (Pubitemid 30122724)
108. WuDunn D. Mechanobiology of trabecular meshwork cells. Exp. Eye Res. 88, 718-723 (2009).
109. Hellberg MR, McLaughlin MA, Sharif NA et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv. Ophthalmol. 47(Suppl. 1), S13-S33 (2002). (Pubitemid 35232216)
110. Sharif NA, Xu SX, Crider JY, McLaughlin M, Davis TL. Levobetaxolol (Betaxon™) and other b-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes. J. Ocular Pharmacol. Ther. 17, 305-317 (2001). (Pubitemid 32888804)
111. Toris CB, Zhan GL, Camras CB, McLaughlin MA. Effects of travoprost on aqueous humor dynamics in monkeys. J. Glaucoma 14, 70-73 (2005). (Pubitemid 40165496)
112. Regina MJ, Winter JC, Rabin RA. Characterization of a novel effect of serotonin 5-HT1A and 5-HT2A receptors: increasing cGMP levels in rat frontal cortex. Neuropharmacology 45, 1041-1049 (2003). (Pubitemid 37412249)
113. Dismuke WM, Mbadugha CC, Ellis DZ. NO-induced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the BKCa ion channel. Am. J. Physiol. Cell Physiol. 294, C1378-C1386 (2008).
114. Dismuke WM, Sharif NA, Ellis DZ. Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58-2667 involves the BKCa ion channel. Invest. Ophthalmol. Vis. Sci. 50, 3353-3359 (2009).
115. Toris CB, Zhan GL, McLaughlin MA. Effects of brinzolamide on aqueous humor dynamics in monkeys and rabbits. J. Ocular Pharmacol. Ther. 19, 397-404 (2003). (Pubitemid 37315129)
116. Sharif NA, Williams GW, Crider JY, Xu SX, Davis TL. Molecular pharmacology of the ocular hypotensive DP/EP2 class prostaglandin AL-6598 and localization of DP and EP2 receptor sites in human eyes. J. Ocular Pharmacol. Ther. 20, 489-508 (2004). (Pubitemid 39628495)
117. Toris CB, Zhan GL, Feilmeier MR, Camras CB, McLaughlin MA. Effects of a prostaglandin DP receptor agonist, AL-6598, on aqueous humor dynamics in a nonhuman primate model of glaucoma. J. Ocul. Pharmacol. Ther. 22, 86-92 (2006). (Pubitemid 43742944)
118. Selliah RD, Hellberg MR, Sharif NA et al. AL-12182, a novel 11-oxa prostaglandin analog with topical ocular hypotensive activity in the monkey. Bioorgan. Med. Chem. Lett. 14, 4525-4528 (2004). (Pubitemid 39043978)
119. Sharif NA, McLaughlin MA, Kelly CR, Xu SX, Crider JY, Parker J. Preclinical pharmacology of AL-12182, a new ocular hypotensive 11-oxa-prostaglandin analog. J. Ocular Pharmacol. Ther. 22, 291-309 (2006). (Pubitemid 44706521)
120. May JA, Dean TR, Sharif NA, Chen H-W. Serotonergic 5-HT7 receptor compounds for treating ocular and CNS disorders. US Patent 7060704 (2006).
121. Evans DW, Hosking SL, Gherghel D, Bartlett JD. Contrast sensitivity improves after brimonidine therapy in primary open-angle glaucoma: a case for neuroprotection. Br. J. Ophthalmol. 87, 1463-1465 (2003). (Pubitemid 38010548)
122. Croxtall JD, Scott LJ. Brinzolamide/ timolol: in open-angle glaucoma and ocular hypertension. Drugs Aging 26, 437-446 (2009).
123. Ferrer E. Trabecular meshwork as a new target for the treatment of glaucoma. Drug News Perspect. 19, 151-158 (2006). (Pubitemid 43886097)
124. Dalhmann-Noor AH, Vijay S, Strid Limb G, Khaw PT. Strategies for optic nerve rescue and regeneration in glaucoma and optic neuropathies. Drug Discov. Today 15, 287-299 (2010).
125. Cho KS, Chen DF. Promoting optic nerve regeneration in adult mice with a pharmaceutical approach. Neurochem. Res. 33, 2126-2133 (2008).
126. Charalambous P, Hurst LA, Thanos S. Engrafted chicken neural tube-derived stem cells support the innate propensity for axonal regeneration within the rat optic nerve. Invest. Ophthalmol. Vis. Sci. 49, 3513-3524 (2008).
127. Osborne NN, Cazevielle C, Carvalho AL et al. In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res. 751, 113-123 (1997). (Pubitemid 27122142)
128. Agarwal N, Krishnamoorthy RR, Landers R et al. Levobetaxolol-induced up-regulation of retinal bFGF and CNTF mRNAs and preservation of retinal function against a photic-induced retinopathy. Exp. Eye Res. 74, 445-453 (2002). (Pubitemid 34757022)
129. Nagata T, Ueno S, Morita H et al. Direct inhibition of N-methyl-d-aspartate (NMDA)-receptor function by antiglaucomatous b-antagonists. J. Pharmacol. Sci. 106, 423-434 (2008). (Pubitemid 351468595)
130. Mackenzie P, Cioffi G. How does lowering of intraocular pressure protect the optic nerve? Surv. Ophthalmol. 53(Suppl. 1), S39-S43 (2008).
131. Smith PD, Sun F, Park KK et al. SOCS3 deletion promotes optic nerve regeneration. Neuron 64, 617-623 (2009).
132. Takayama Y, Yukuo Y, Masayoshi U. Visual function disorder improving agents. US Patent 7109208 (2006).
133. Azuma M, Yoshida Y, Waki M, Uehata M. Agents for prophylaxis and treatment of glaucoma. US Patent 6649625 (2003).
134. Osborne NN. Mitochondria: their role in ganglion cell death and survival in primary open angle glaucoma. Exp. Eye Res. 90, 750-757 (2010).